Progyny runs fertility benefits for US employers, like a concierge that guides employees through IVF and adoption while managing the costs for companies. Think of it as a specialized health insurance middleman for family-building.
Money comes from employer contracts for fertility and pharmacy benefits, with revenue growing from USD 1.09B in 2023 to USD 1.29B in 2025. Gross margins are thin at ~24%, but net margins improved to 8% in Q2 2026, showing recurring subscription-like income.
Progyny's network of top fertility clinics and its data on treatment outcomes create switching costs for employers, but UnitedHealth's Optum and Carrot Fertility offer similar bundled services, and employers can self-insure to bypass them. moat_level: eroding
Key events, in time order
None yet
None yet
Progyny (PGNY) saw analyst initiations from Wells Fargo at Overweight, indicating positive sentiment following a period of similar analyst actions.
Main discussion
Analyst Calls of the Day with @JD_Durkin: ➡️ UMB Financial $UMBF: J.P. Morgan initiates at Overweight ➡️ Progyny $PGNY: Wells Fargo initiates at Overweight ➡️ Merck $MRK: Morgan Stanley upgrades to Overweight
+Initiations 8/20: $ACOG $BTDR $CALC $CVLG $DPRO $EBAY $ELOX $ETSY $FRNM $INCY $KDP $LWAY $MIST $MSGE $MPWR $PGNY $PRQR $QNCX $SHOP $SITM $SPHR $SRZN $TGB $UMBF $VVV $W $XMTR . -Initiations 8/20:
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
